ArticleAnimal cells and systems2025
Differential effects of nesfatin-1 on proliferation and migration in normal and cancerous human lung cells via the PI3K/AKT pathway.
Article in Animal cells and systems, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nesfatin-1, initially identified as an appetite-regulating hormone, has also been detected in various cancer tissues and implicated in tumorigenesis. However, its role in the proliferation and migration of lung cancer cells remains unclear. This study aims to investigate the effects of nesfatin-1 on the proliferation and migration of human lung cancer cells and elucidate the underlying molecular mechanisms. The expression of nesfatin-1 protein and NUCB2 mRNA was detected in the immortalized normal human bronchial cell line BEAS-2B and the non-small-cell lung cancer cell line H1299. Immunohistochemical staining revealed the localization of nesfatin-1 binding sites in both cell lines. Nesfatin-1 treatment significantly increased the proliferation and migration of BEAS-2B cells but not of H1299 cells. The expression levels of cell proliferation-related genes, such as TGFα, PXN, MTOR, and CCND1, were upregulated in BEAS-2B cells, with no significant changes observed in H1299 cells. In addition, phosphorylation of FAK, PI3 K, and AKT was increased in BEAS-2B cells, whereas only FAK phosphorylation was increased in H1299 cells. To further assess the role of endogenous nesfatin-1, NUCB2 expression was silenced using small interfering RNA. Knockdown of NUCB2 suppressed proliferation and migration of BEAS-2B cells, as well as their expression of TGFα, PXN, MTOR, and CCND1; however, it had no significant effect on H1299 cells. These results suggest that nesfatin-1 promotes proliferation and migration in normal lung epithelial cells but not in lung cancer cells. Further research is needed to elucidate the molecular mechanisms underlying the differential effects of nesfatin-1 on normal and cancerous lung cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.